Life Science Nation Newsletter  |  February 4, 2016  |  Issue 148

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Jan. 28 - Feb. 3)
Seeks Series A-B Deals In Cardiac Devices & Neuromodulation
Seeks Partnerships in Orthopedics, Inflammation, Dermatology, and Surgery
Invests at the Intersection of Data and Healthcare
Invests In Health Startups Targeting the China Market
In This Issue
LSN Videos
RESI San Francisco 2016 Investors Panel

Video Recap of RESI@TMCx 2015

By Dennis Ford, Founder & CEO, LSN

I recently presented on Fundraising Best Practices at the FreeMind Group's 11th annual Non-Dilutive Funding Summit in San Francisco, to an audience comprised of scientist-entrepreneurs and fundraising CEOs. The Fundraising Best Practices session helped create context and understanding for these entrepreneurs around issues related to branding and messaging of their firms. The presentation also explains why organizing a global target list of investors that are a fit for your sector and stage is vital to an efficient fundraising process. Last but not least, I discussed and debunked some of the myths around fundraising, what works, and what doesn't work.

Many of the concepts covered in the presentation are expanded upon in LSN's book, The Life Science Executive's Fundraising Manifesto...

Fundraising Best Practices
Fundraising Best Practices

By Christine A. Wu, Research Analyst, LSN

At RESI San Francisco, a panel of Venture Philanthropy investors engaged in a stimulating conversation addressing patient access for underserved populations, assessment of "positively impactful" technologies, and their relationships with traditional venture capital investors, among many other topics.

Moderated by Christopher de Souza of Broadview Ventures, panelists include:
  • Lindy Fishburne, Executive Director, Thiel Foundation & Breakout Labs
  • Rachel Rimsky, Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson's Research
  • Daniel Smith, VP of Innovative Technologies, Autism Speaks
  • Patricia Zilliox, Chief Drug Development Officer, Foundation Fighting Blindness

By Shaoyu Chang, MD, MPH, Senior Research Manager, LSN

This year's JPM saw more than 1000 attendees from China. As the world's second largest healthcare market continues to grow at a steady pace, Greater China-based investors have shown an expanding appetite for biomedical deals. Despite regional differences, we have observed a few common, interesting trends based on our interaction with investors from China, Hong Kong, and Taiwan.

New Players Enter the Arena

Against the backdrop of the recent market turmoil, Chinese regulators are laying the groundwork to attract capital for small innovative businesses, such as the Strategic Emerging Board to be launched in the second half of 2016. Investors are optimistic. Traditional healthcare VCs based in China have successfully raised new funds. The space is now crowded with new investors from other industries, ranging from information technology and manufacturing to textile and real estate. They all want to seize the opportunity of long-term growth in healthcare...